Learn about cost, uses, and more for Amjevita (adalimumab-atto), a prescription drug that treats certain inflammatory conditions, such as rheumatoid arthritis.

Amgen’s long-awaited Humira biosimilar, Amjevita, has finally hit the market. After years of sitting on the biosimilar, which won an FDA approval in 2016, Amgen is ready to make waves.

Find patient medical information for Amjevita(CF) Autoinjector subcutaneous on WebMD including its uses, side effects and safety, interactions, pictures, warnings and user ratings.

Amjevita is a prescription drug used to treat certain inflammatory conditions, including rheumatoid arthritis. Learn about the common, mild, and serious side effects it can cause and how to manage ...

The new drug, Amjevita, will be sold at a list price from $1,558 to $3,288 for a 40 milligram, two-week supply of the injectable drug, Amgen said, representing discounts of 5% or 55% from Humira's ...

Amjevita is supplied as a 40mg/0.8mL single-dose prefilled SureClick autoinjector, and as 20mg/0.4mL and 40mg/0.8mL single-dose prefilled syringes.

Amgen said its drug, Amjevita, or adalimumab-atto, will have two list prices -- $3,288 and $1,557 per 40 milligram pen device for a two-week supply -- representing a discount of 5% and 55% to ...

At the beginning of July, seven additional Humira ® (adalimumab) biosimilars, including one interchangeable, joined Amjevita™ (adalimumab-atto) in the US marketplace. Abrilada™ (adalimumab ...

Despite being approved in 2016, the first adalimumab (Humira) biosimilar, Amjevita from Amgen, has finally launched in the United States.All of the adalimumab biosimilars had reached settlement ...

Amgen Inc on Tuesday said it was launching Amjevita, or adalimumab-atto, a biosimilar version of AbbVie Inc's big selling arthritis treatment Humira, the first such biosimilar competition for the ...

At the end of January, Amgen (AMGN-1.03%) celebrated the U.S. launch of its biosimilar Amjevita to AbbVie's (ABBV 2.64%) star immunology drug called Humira. Amgen's Amjevita received approval from ...

Humira has been the world’s best selling medicine since it arrived on the market in 2002. Now, it is finally getting competition with the release of Amgen’s biosimilar drug, Amjevita. Humira ...